Capturing Quality of Life and Priorities for Clinical Research in Parents and Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD PROM)

November 18, 2026 updated by: Children's Hospital of Philadelphia

Chronic kidney disease (CKD) in childhood is a significant burden and reduces the quality of life for both children and their parents. CKD is especially burdensome when it progresses to end stage kidney disease (ESKD, previously referred to as end-stage renal disease or ESRD), placing considerable demands on a childs entire family. Although studies are available for all-cause CKD and for some disease subsets, there is no study capturing quality of life in children or adolescents specifically affected by autosomal recessive polycystic kidney disease (ARPKD). These children are often severely affected prenatally and postnatally have problems due to massive kidney enlargement, hypertension, kidney failure, and portal hypertension. They often need to receive kidney replacement therapy during childhood.

The need to include patients and their lived experience in the design of clinical trials exists for all diseases, but is implemented infrequently, especially in the field of rare diseases. The negative consequences of limited patient/parent input in clinical trial design for rare diseases has been recently highlighted by a report from the International Rare Diseases Research Consortium (IRDiRC).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The first primary objective of this study is to assess the quality of life of children affected by autosomal recessive polycystic kidney disease (ARPKD) and their parents, using validated survey instruments.

The second primary objective is to determine priorities of patients, caregivers, and healthcare professionals regarding outcome measures in order to determine a set of core outcomes for future ARPKD-related clinical trials The secondary aim is to validate the use of existing quality of life questionnaire for this cohort of children with ARPKD and to compare their hrQoL to previously published cohorts of children with all-cause chronic kidney disease.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19146
        • Recruiting
        • Children's Hospital of Philadelphia
        • Contact:
        • Principal Investigator:
          • Lisa Guay-Woodford, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second to 25 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subjects should be between 0-25 years of age and have an ICD-10 diagnosis code for ARPKD in the CHOP Epic EHR.

Description

Inclusion Criteria:

  • Subjects should be over 18 years of age and permanently live in the same household as the child/ young person with ARPKD.

Exclusion Criteria:

  • Insufficient understanding of the questions due to intellectual capabilities or language barriers. However, translation by a professional interpreter is permissible.

Lack of written informed consent. Subjects that choose not to have their responses recorded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: FAMILY_BASED
  • Time Perspectives: OTHER

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with ARPKD and their caregivers

Families will be asked to fill out a series of questionnaires

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PedsQL ESRD Questionnaire
Time Frame: 5 years

PedsQL ESRD Module (quality of life in children with end-stage renal disease) validated questionnaire on health-related QOL for children ≥ 24 months and adults < 25 years with renal disease. 35 questions. Ranking scale (not at all, sometimes, a lot). Items are reverse-scored and linearly transformed to a 0 to 100 scale, where higher scores indicate a better quality of life.

5 years
SDQ (strength and difficulties questionnaire)
Time Frame: 5 years

validated brief emotional and behavioral screening tool. 38 questions. Ranking scale (not true, somewhat true, certainly true). Items divided into five scales of five items each, scored from 0 to 10 per scale, with four problem scales summed into a Total Difficulties score from 0 to 40. Higher scores indicate greater difficulty.

5 years
IFS (impact on family scale)
Time Frame: 5 years

Caregiver burden will be captured by recording the burden on family life with the "Impact on Family Scale"(IFS). 35 questions. Ranking scale (strongly agree, agree, disagree, strongly disagree). Scored by rating each item on a 4-point Likert scale and summing the items to get a total score, where higher scores indicate a greater perceived impact of a child's health condition or disability on the family.

5 years
ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children)
Time Frame: 5 years

Caregiver burden will be captured by recording the burden on family life with ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children). 29 questions. Ranking scale (never, rarely, sometimes, often, always). 5-point rating scale (0 = "never" to 4 = "always") based on the past 7 days, where higher scores indicate better parental quality of life.

5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lisa Guay-Woodford, M.D., CHOP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 6, 2024

Primary Completion (Estimated)

November 6, 2030

Study Completion (Estimated)

November 6, 2030

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

November 18, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 18, 2026

Last Verified

November 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe